Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07339722 · ClinicalTrials.gov registry record · Phase 1

A Study of LY4515100 in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT07339722: Recruiting Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

NCT07339722 is a Phase 1 study of Healthy that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 40 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07339722, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will include six overnight stays.

Primary Outcome

SAEs of LY4515100

Conditions Studied

Healthy

Interventions

  • DRUG LY4515100 via SAD
  • DRUG LY4515100 via MAD

Study Locations (1)

Texas

  • Fortrea Clinical Research Unit - Dallas

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-01-15
Est. Completion 2026-07
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What NCT07339722 shows while recruiting

NCT07339722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which LY4515100 via SAD is the first listed.

NCT07339722 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07339722 about?

NCT07339722 is a clinical study titled "A Study of LY4515100 in Healthy Participants". The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will inclu...

What is the current status of trial NCT07339722?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-01-15. Estimated completion is 2026-07.

What conditions does trial NCT07339722 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT07339722?

The interventions under investigation include: LY4515100 via SAD (DRUG), LY4515100 via MAD (DRUG).

Who is sponsoring clinical trial NCT07339722?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07339722 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07339722's enrollment target sits among peer trials

40 540th of 1090 higher than 513 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07339722

Source: ClinicalTrials.gov NCT07339722, the US trial registry maintained by the National Library of Medicine. NCT07339722 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.